Cytomx Therapeutics, Inc.

University of California

Daniel Robert Hostetter

Olga Vasiljeva

Stephen James Moore

Jason Gary Sagert

Margaret Thy Luu Nguyen

James William West

Jonathan Alexander Terrett

Charles S Craik

Sherry Lynn La Porte

Bryan Allen Irving

Jeanne Grace Flandez

Li Mei

Margaret T L Nguyen

Natalia Sevillano

Aaron M Lebeau

Olivia Jennifer Razo

Jennifer Hope Richardson

Clayton William White

Henry Bernard Lowman

Chihunt Wong

Chihong Wong

The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.

Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof

The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator (uPA), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator in a variety of therapeutic, diagnostic and prophylactic indications.

Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof

The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one matrix metalloprotease (MMP), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one MMP protease, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one MMP protease in a variety of therapeutic, diagnostic and prophylactic indications.

Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof

The invention relates generally to antibodies, activatable antibodies, multispecific antibodies, and multispecific activatable antibodies that specifically bind to at least CD3, as well as to methods of making and using these antibodies, activatable antibodies, multispecific antibodies, and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same

The invention relates generally to antibodies that bind programmed death ligand 1 (PDL1), activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 antibodies and anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof

The invention relates generally to multispecific antibodies and to multispecific activatable antibodies that specifically bind to two or more different antigens or epitopes, as well as to methods of making and using these multispecific antibodies and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Multispecific antibodies, multispecific activatable antibodies and methods of using the same

The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to interleukin-6 receptor (IL-6R), and to methods of making and using these anti-IL-6R activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Activatable antibodies that bind interleukin-6 receptor and methods of use thereof

Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of  thereof

Growing community of inventors

Palo Alto, CA, United States of America

Daniel Robert Hostetter